Publications

  • Yoel A. Klug; Roland Schwarzer; Etai Rotem; Meital Charni; Alon Nudelman; Andrea Gramatica; Batya Zarmi; Varda Rotter; Yechiel Shai (2019). The HIV gp41 Fusion Protein Inhibits T-Cell Activation through the Lentiviral Lytic Peptide 2 Motif.  Biochemistry. 2019, 58 (6):818-832.
  • Hilla Solomon; Nathan Dinowitz; Ioannis S. Pateras; Tomer Cooks; Yoav Shetzer; Alina Molchadsky; Meital Charni; Stav Rabani; Gabriela Koifman; Ohad Tarcic; Ziv Porat; Ira Kogan-Sakin; Naomi Goldfinger; Moshe Oren; Curtis C. Harris; Vassilis G. Gorgoulis; Varda Rotter (2018). Mutant p53 gain of function underlies high expression levels of colorectal cancer stem cells markers.  Oncogene. 2018, 37 (12):1669-1684.
  • Meital Charni-Natan; Hilla Solomon; Alina Molchadsky; Adi Jacob-Berger; Naomi Goldfinger; Varda Rotter (2018). Various stress stimuli rewire the profile of liver secretome in a p53-dependent manner.  Cell Death and Disease. 2018, 9 .
  • Gabriela Koifman; Yoav Shetzer; Shay Eizenberger; Hilla Solomon; Ron Rotkopf; Alina Molchadsky; Giuseppe Lonetto; Naomi Goldfinger; Varda Rotter (2018). A Mutant p53-Dependent Embryonic Stem Cell Gene Signature Is Associated with Augmented Tumorigenesis of Stem Cells.  Cancer Research. 2018, 78 (20):5833-5847.
  • Etai Rotem; Omri Faingold; Meital Charni; Yoel A. Klug; Daniel Harari; Liraz Shmuel-Galia; Alon Nudelman; Varda Rotter; Yechiel Shai (2018). The HTLV-1 gp21 fusion peptide inhibits antigen specific T-cell activation in-vitro and in mice.  PLoS Pathogens. 2018, 14 (5).
  • Ronit Aloni-Grinstein; Meital Charni-Natan; Hilla Solomon; Varda Rotter (2018). p53 and the Viral Connection: Back into the Future.  Cancers. 2018, 10 (6).
  • Yoav Shetzer; Yael Napchan; Tom Kaufman; Alina Molchadsky; Perry Tal; Naomi Goldfinger; Varda Rotter (2017). Immune deficiency augments the prevalence of p53 loss of heterozygosity in spontaneous tumors but not bi-directional loss of heterozygosity in bone marrow progenitors.  International Journal of Cancer. 2017, 140 (6):1364-1369.
  • Meital Charni; Ronit Aloni-Grinstein; Alina Molchadsky; Varda Rotter (2017). p53 on the crossroad between regeneration and cancer.  Cell Death and Differentiation. 2017, 24 (1):8-14.
  • Hilla Solomon; Bastian Brauning; Irit Fainer; Gili Ben-Nissan; Stav Rabani; Naomi Goldfinger; Oren Moscovitz; Zippora Shakked; Varda Rotter; Michal Sharon (2017). Post-translational regulation of p53 function through 20S proteasome-mediated cleavage.  Cell Death and Differentiation. 2017, 24 (12):2187-2198.
  • Inbal Wortzel; Gabriela Koifman; Varda Rotter; Rony Seger; Ziv Porat (2017). High Throughput Analysis of Golgi Structure by Imaging Flow Cytometry.  Scientific Reports. 2017, 7 .
  • Pratik Vyas; Itai Beno; Zhiqun Xi; Yan Stein; Dmitrij Golovenko; Naama Kessler; Varda Rotter; Zippora Shakked; Tali E. Haran (2017). Diverse p53/DNA binding modes expand the repertoire of p53 response elements.  Proceedings of the National Academy of Sciences of the United States of America. 2017, 114 (40):10624-10629.
  • Perry Tal; Shay Eizenberger; Elad Cohen; Naomi Goldfinger; Shmuel Pietrokovski; Moshe Oren; Varda Rotter (2016). Cancer therapeutic approach based on conformational stabilization of mutant p53 protein by small peptides.  Oncotarget. 2016, 7 (11):11817-11837.
  • Meital Charni; Alina Molchadsky; Ido Goldstein; Hilla Solomon; Perry Tal; Naomi Goldfinger; P. Yang; Ziv Porat; G. Lozano; Varda Rotter (2016). Novel p53 target genes secreted by the liver are involved in non-cell-autonomous regulation.  Cell Death and Differentiation. 2016, 23 (2):509-520.
  • Francesca Grespi; Vivien Landre; Alina Molchadsky; Daniele, Nicola Di Daniele; Luigi Tonino Marsella; Gerry Melino; Varda Rotter (2016). Differential regulated microRNA by wild type and mutant p53 in induced pluripotent stem cells.  Cell Death & Disease. 2016, 7 .
  • Kristin Stock; Marta F. Estrada; Suzana Vidic; Kjersti Gjerde; Albin Rudisch; Vitor E. Santo; Michael Barbier; Sami Blom; Sharath C. Arundkar; Irwin Selvam; Annika Osswald; Yan Stein; Sylvia Gruenewald; Catarina Brito; Weerden, Wytske van Weerden; Varda Rotter; Erwin Boghaert; Moshe Oren; Wolfgang Sommergruber; Yolanda Chong; Hoogt, Ronald de Hoogt; Ralph Graeser (2016). Capturing tumor complexity in vitro: Comparative analysis of 2D and 3D tumor models for drug discovery.  Scientific Reports. 2016, 6 .
  • Mathieu Morel; Roman Shtrahman; Varda Rotter; Lior Nissim; Roy H Bar-Ziv (2016). Cellular heterogeneity mediates inherent sensitivity-specificity tradeoff in cancer targeting by synthetic circuits..  Proceedings of the National Academy of Sciences of the United States of America. 2016, 113 (29):8133-8.
  • Yoav Shetzer; Alina Molchadsky; Varda Rotter (2016). Oncogenic Mutant p53 Gain of Function Nourishes the Vicious Cycle of Tumor Development and Cancer Stem-Cell Formation.  Cold Spring Harbor perspectives in medicine. 2016, 6 (10):2016.
  • Moshe Oren; Perry Tal; Varda Rotter (2016). Targeting mutant p53 for cancer therapy.  AGING-US. 2016, 8 (6):1159-1160.
  • Noa Rivlin; Gabriela Koifman; Varda Rotter (2015). p53 orchestrates between normal differentiation and cancer.  Seminars in Cancer Biology. 2015, 32 :10-17.
  • Varda Rotter (2014). The mutant p53-cancer stem cells and drug resistance paradigm.  European Journal of Cancer. 2014, 50 :S11-S11.
  • Ronit Aloni-Grinstein; Yoav Shetzer; Tom Kaufman; Varda Rotter (2014). p53: The barrier to cancer stem cell formation.  FEBS Letters. 2014, 588 (16):2580-2589.
  • Yoav Shetzer; Sivan Kagan; Gabriela Koifman; Rachel Sarig; I. Kogan-Sakin; Meital Charni; Tom Kaufman; M. Zapatka; Alina Molchadsky; Noa Rivlin; Nathan Dinowitz; Sarit Levin; Gilad Landan; Ido Goldstein; Naomi Goldfinger; D. Pe'er; B. Radlwimmer; P. Lichter; Varda Rotter; Ronit Aloni-Grinstein (2014). The onset of p53 loss of heterozygosity is differentially induced in various stem cell types and may involve the loss of either allele.  Cell Death and Differentiation. 2014, 21 (9):1419-1431.
  • Hilla Solomon; Michal Sharon; Varda Rotter (2014). Modulation of alternative splicing contributes to cancer development: focusing on p53 isoforms, p53β and p53γ.  Cell Death and Differentiation. 2014, 21 (9):1347-1349.
  • Noa Rivlin; Shir Katz; Maayan Doody; Michal Sheffer; Stav Horesh; Alina Molchadsky; Gabriela Koifman; Yoav Shetzer; Naomi Goldfinger; Varda Rotter; Tamar Geiger (2014). Rescue of embryonic stem cells from cellular transformation by proteomic stabilization of mutant p53 and conversion into WT conformation.  Proceedings of the National Academy of Sciences of the United States of America. 2014, 111 (19):7006-7011.
  • Shunbin Xiong; Huolin Tu; Madhusudhan Kollareddy; Vinod Pant; Qin Li; Yun Zhang; James G. Jackson; Young-Ah Suh; Ana C. Elizondo-Fraire; Peirong Yang; Gilda Chau; Mehrnoosh Tashakori; Amanda R. Wasylishen; Zhenlin Ju; Hilla Solomon; Varda Rotter; Bin Liu; Adel K. El-Naggar; Lawrence A. Donehower; Luis Alfonso Martinez; Guillermina Lozano (2014). Pla2g16 phospholipase mediates gain-of-function activities of mutant p53.  Proceedings of the National Academy of Sciences of the United States of America. 2014, 111 (30):11145-11150.
  • Yoav Shetzer; Hilla Solomon; Gabriela Koifman; Alina Molchadsky; Stav Horesh; Varda Rotter (2014). The paradigm of mutant p53-expressing cancer stem cells and drug resistance.  Carcinogenesis. 2014, 35 (6):1196-1208.
  • S Vidic; N Esser; Hoogt, R de Hoogt; I Verberne; I Kogan-Sakin; Yan Stein; Varda Rotter; M Barbier; Y Chong; SD Breucker; K Smans; M Akerfelt; M Nees; P King; I Hickson; Weerden, W van Weerden; R Graeser (2014). Complex in vitro and in vivo prostate cancer models for the PREDECT consortium.  Cancer Research. 2014, 74 (19).
  • MR Hellem; JR Olsen; YP Hua; Y Qu; K Marvyin; K Rostad; J Liu; LS Li; Varda Rotter; BY Lin; XS Ke; AM Oyan; KH Kalland (2014). Restriction of androgen receptor and target gene expression.  Cancer Research. 2014, 74 (19).
  • Tal Leibovich-Rivkin; Yulia Liubomirski; Tsipi Meshel; Anastasia Abashidze; Daphna Brisker; Hilla Solomon; Varda Rotter; Miguel Weil; Adit Ben-Baruch (2014). The inflammatory cytokine TNF alpha cooperates with Ras in elevating metastasis and turns WT-Ras to a tumor-promoting entity in MCF-7 cells.  BMC Cancer. 2014, 14 .
  • Fumin Chang; Christopher A. Lemmon; Voraphoj Nilaratanakul; Varda Rotter; Lewis Romer (2014). Endothelial Matrix Assembly during Capillary Morphogenesis: Insights from Chimeric TagRFP-Fibronectin Matrix.  Journal Of Histochemistry & Cytochemistry. 2014, 62 (11):774-790.
  • Tomer Cooks; Ioannis S. Pateras; Ohad Tarcic; Hilla Solomon; Aaron J. Schetter; Sylvia Wilder; Guillermina Lozano; Eli Pikarsky; Tim Forshew; Nitzan Rozenfeld; Noam Harpaz; Steven Itzkowitz; Curtis C. Harris; Varda Rotter; Vassilis G. Gorgoulis; Moshe Oren (2013). Mutant p53 Prolongs NF-kappa B Activation and Promotes Chronic Inflammation and Inflammation-Associated Colorectal Cancer.  Cancer Cell. 2013, 23 (5):634-646.
  • Shalom Madar; Ido Goldstein; Varda Rotter (2013). 'Cancer associated fibroblasts' - more than meets the eye.  Trends in Molecular Medicine. 2013, 19 (8):447-453.
  • Ran Brosh; Y. Assia-Alroy; Alina Molchadsky; Chamutal Bornstein; Elya Dekel; Shalom Madar; Yoav Shetzer; Noa Rivlin; Naomi Goldfinger; Rachel Sarig; Varda Rotter (2013). p53 Counteracts reprogramming by inhibiting mesenchymal-to-epithelial transition.  Cell Death and Differentiation. 2013, 20 (2):312-320.
  • Alina Molchadsky; Osnat Ezra; P. G. Amendola; D. Krantz; I. Kogan-Sakin; Y. Buganim; Noa Rivlin; Naomi Goldfinger; V. Folgiero; R. Falcioni; Rachel Sarig; Varda Rotter (2013). p53 is required for brown adipogenic differentiation and has a protective role against diet-induced obesity.  Cell Death and Differentiation. 2013, 20 (5):774-783.
  • Ido Goldstein; Noa Rivlin; Or-yam Shoshana; Osnat Ezra; Shalom Madar; Naomi Goldfinger; Varda Rotter (2013). Chemotherapeutic agents induce the expression and activity of their clearing enzyme CYP3A4 by activating p53.  Carcinogenesis. 2013, 34 (1):190-198.
  • Shalom Madar; Einav Harel; Ido Goldstein; Yan Stein; Ira Kogan-Sakin; Iris Kamer; Hilla Solomon; Elya Dekel; Perry Tal; Naomi Goldfinger; Gilgi Friedlander; Varda Rotter (2013). Mutant p53 Attenuates the Anti-Tumorigenic Activity of Fibroblasts- Secreted Interferon Beta.  PLoS One. 2013, 8 (4).
  • Jan Roger Olsen; Anne Margrete Oyan; Kari Rostad; Margrete R. Hellem; Jie Liu; Lisha Li; David R. Micklem; Hallvard Haugen; James B. Lorens; Varda Rotter; Xi-Song Ke; Biaoyang Lin; Karl-Henning Kalland (2013). p63 Attenuates Epithelial to Mesenchymal Potential in an Experimental Prostate Cell Model.  PLoS One. 2013, 8 (5).
  • Ido Goldstein; Osnat Ezra; Noa Rivlin; Alina Molchadsky; Shalom Madar; Naomi Goldfinger; Varda Rotter (2012). p53, a novel regulator of lipid metabolism pathways.  Journal of Hepatology. 2012, 56 (3):656-662.
  • Ido Goldstein; Shalom Madar; Varda Rotter (2012). Cancer research, a field on the verge of a paradigm shift?.  Trends in Molecular Medicine. 2012, 18 (6):299-303.
  • Ido Goldstein; Varda Rotter (2012). Regulation of lipid metabolism by p53-fighting two villains with one sword.  Trends in Endocrinology and Metabolism. 2012, 23 (11):567-575.
  • G. Blandino; W. Deppert; P. Hainaut; A. Levine; G. Lozano; M. Olivier; Varda Rotter; K. Wiman; Moshe Oren (2012). Mutant p53 protein, master regulator of human malignancies: a report on the fifth Mutant p53 Workshop.  Cell Death and Differentiation. 2012, 19 (1):180-183.
  • Gilad Landan; Netta Mendelson Cohen; Zohar Mukamel; Amir Bar; Alina Molchadsky; Ran Brosh; Shirley Horn-Saban; Daniela Amann Zalcenstein; Naomi Goldfinger; Adi Zundelevich; Einav Nil Gal-Yam; Varda Rotter; Amos Tanay (2012). Epigenetic polymorphism and the stochastic formation of differentially methylated regions in normal and cancerous tissues.  Nature Genetics. 2012, 44 (11):1207-1214.
  • Nataly Kravchenko-Balasha; Alexander Levitzki; Andrew Goldstein; Varda Rotter; F. Remacle; R. D. Levine (2012). On a fundamental structure of gene networks in living cells.  Proceedings of the National Academy of Sciences of the United States of America. 2012, 109 (12):4702-4707.
  • Isabel Heidegger; Philipp Ofer; Wolfgang Doppler; Varda Rotter; Helmut Klocker; Petra Massoner (2012). Diverse Functions of IGF/Insulin Signaling in Malignant and Noncancerous Prostate Cells: Proliferation in Cancer Cells and Differentiation in Noncancerous Cells.  Endocrinology. 2012, 153 (10):4633-4643.
  • Hilla Solomon; Yosef Buganim; Ira Kogan-Sakin; Leslie Pomeraniec; Yael Assia; Shalom Madar; Ido Goldstein; Ran Brosh; Eyal Kalo; Tsevi Beatus; Naomi Goldfinger; Varda Rotter (2012). Various p53 mutant proteins differently regulate the Ras circuit to induce a cancer-related gene signature.  Journal of Cell Science. 2012, 125 (13):3144-3152.
  • Eyal Kalo; Ira Kogan-Sakin; Hilla Solomon; Elad Bar-Nathan; Moshe Shay; Yoav Shetzer; Elya Dekel; Naomi Goldfinger; Yossi Buganim; Perry Stambolsky; Ido Goldstein; Shalom Madar; Varda Rotter (2012). Mutant p53(R273H) attenuates the expression of phase 2 detoxifying enzymes and promotes the survival of cells with high levels of reactive oxygen species.  Journal of Cell Science. 2012, 125 (22):5578-5586.
  • Hilla Solomon; Shalom Madar; Varda Rotter (2011). Mutant p53 gain of function is interwoven into the hallmarks of cancer.  Journal of Pathology. 2011, 225 (4):475-478.
  • Xi-song Ke; Wen-cheng Li; Randi Hovland; Yi Qu; Run-hui Liu; Emmet McCormack; Frits Thorsen; Jan Roger Olsen; Anders Molven; Ira Kogan-Sakin; Varda Rotter; Lars A. Akslen; Anne Margrete Oyan; Karl-Henning Kalland (2011). Reprogramming of cell junction modules during stepwise epithelial to mesenchymal transition and accumulation of malignant features in vitro in a prostate cell model.  Experimental Cell Research. 2011, 317 (2):234-247.
  • Rachel Sarig; Varda Rotter (2011). Can an iPS cell secure its genomic fidelity?.  Cell Death and Differentiation. 2011, 18 (5):743-744.
  • Ido Goldstein; V. Marcel; M. Olivier; Moshe Oren; Varda Rotter; P. Hainaut (2011). Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies.  Cancer Gene Therapy. 2011, 18 (1):2-11.
  • Stefania Dell'Orso; Giulia Fontemaggi; Perry Stambolsky; Frauke Goeman; Christine Voellenkle; Massimo Levrero; Sabrina Strano; Varda Rotter; Moshe Oren; Giovanni Blandino (2011). ChIP-on-Chip Analysis of In Vivo Mutant p53 Binding To Selected Gene Promoters.  Omics-A Journal Of Integrative Biology. 2011, 15 (5):305-312.
  • Yosef Buganim; Shalom Madar; Yoach Rais; Leslie Pomeraniec; Einav Harel; Hilla Solomon; Eyal Kalo; Ido Goldstein; Ran Brosh; Ora Haimov; Camila Avivi; Sylvie Polak-Charcon; Naomi Goldfinger; Iris Barshack; Varda Rotter (2011). Transcriptional activity of ATF3 in the stromal compartment of tumors promotes cancer progression.  Carcinogenesis. 2011, 32 (12):1749-1757.
  • Chamutal Bornstein; Ran Brosh; Alina Molchadsky; Shalom Madar; Ira Kogan-Sakin; Ido Goldstein; Deepavali Chakravarti; Elsa R. Flores; Naomi Goldfinger; Rachel Sarig; Varda Rotter (2011). SPATA18, a Spermatogenesis-Associated Gene, Is a Novel Transcriptional Target of p53 and p63.  Molecular and Cellular Biology. 2011, 31 (8):1679-1689.
  • Nataly Kravchenko-Balasha; F. Remacle; Ayelet Gross; Varda Rotter; Alexander Levitzki; R. D. Levine (2011). Convergence of Logic of Cellular Regulation in Different Premalignant Cells by an Information Theoretic Approach.  BMC Systems Biology. 2011, 5 .
  • Ariel Rinon; Alina Molchadsky; Elisha Nathan; Gili Yovel; Varda Rotter; Rachel Sarig; Eldad Tzahor (2011). p53 coordinates cranial neural crest cell growth and epithelial-mesenchymal transition/delamination processes.  Development. 2011, 138 (9):1827-1838.
  • Yuval Tabach; Ira Kogan-Sakin; Yosef Buganim; Hilla Solomon; Naomi Goldfinger; Randi Hovland; Xi-Song Ke; Anne M. Oyan; Karl-H. Kalland; Varda Rotter; Eytan Domany (2011). Amplification of the 20q Chromosomal Arm Occurs Early in Tumorigenic Transformation and May Initiate Cancer.  PLoS One. 2011, 6 (1).
  • Orit Leshem; Shalom Madar; Ira Kogan-Sakin; Iris Kamer; Ido Goldstein; Ran Brosh; Yehudit Cohen; Jasmine Jacob-Hirsch; Marcelo Ehrlich; Shmuel Ben-Sasson; Naomi Goldfinger; Ron Loewenthal; Ephraim Gazit; Varda Rotter; Raanan Berger (2011). TMPRSS2/ERG Promotes Epithelial to Mesenchymal Transition through the ZEB1/ZEB2 Axis in a Prostate Cancer Model.  PLoS One. 2011, 6 (7).
  • Shalom Madar; Hilla Solomon; Varda Rotter (2011). Same stem cells but different: Isogenic embryonic stem cells harboring different p53 mutants.  Cell Cycle. 2011, 10 (14):2248-2249.
  • Shalom Madar; Ido Goldstein; Ortal Neeman; Varda Rotter (2011). Beyond tumor suppression: p53 controls blastocyst implantation.  Cell Cycle. 2011, 10 (24):4203-4203.
  • Shalom Madar; Perry Stambolsky; Varda Rotter (2011). Unleash the wild type: Restoration of p53 suppressive activity in skin cancer.  Cell Cycle. 2011, 10 (5):736-737.
  • Hilla Solomon; Ran Brosh; Yosef Buganim; Varda Rotter (2010). Inactivation of the p53 Tumor Suppressor Gene and Activation of the Ras Oncogene: Cooperative Events in Tumorigenesis.  Discovery medicine. 2010, 48 :448-454.
  • Perry Stambolsky; Yuval Tabach; Giulia Fontemaggi; Lilach Weisz; Revital Maor-Aloni; Zahava Sigfried; Idit Shiff; Ira Kogan; Moshe Shay; Eyal Kalo; Giovanni Blandino; Itamar Simon; Moshe Oren; Varda Rotter (2010). Modulation of the Vitamin D3 Response by Cancer-Associated Mutant p53.  Cancer Cell. 2010, 17 (3):273-285.
  • Ran Brosh; Rachel Sarig; Natan, Elad Bar Natan; Alina Molchadsky; Shalom Madar; Chamutal Bornstein; Yosef Buganim; Tirosh Shapira; Naomi Goldfinger; Ralf Paus; Varda Rotter (2010). p53-dependent transcriptional regulation of EDA2R and its involvement in chemotherapy-induced hair loss.  FEBS Letters. 2010, 584 (11):2473-2477.
  • Ran Brosh; Varda Rotter (2010). Transcriptional control of the proliferation cluster by the tumor suppressor p53.  Molecular BioSystems. 2010, 6 (1):17-29.
  • Rachel Sarig; Noa Rivlin; Ran Brosh; Chamutal Bornstein; Iris Kamer; Osnat Ezra; Alina Molchadsky; Naomi Goldfinger; Ori Brenner; Varda Rotter (2010). Mutant p53 facilitates somatic cell reprogramming and augments the malignant potential of reprogrammed cells.  Journal of Experimental Medicine. 2010, 207 (10):2127-2140.
  • Alina Molchadsky; Noa Rivlin; Ran Brosh; Varda Rotter; Rachel Sarig (2010). p53 is balancing development, differentiation and de-differentiation to assure cancer prevention.  Carcinogenesis. 2010, 31 (9):1501-1508.
  • Moshe Oren; Varda Rotter (2010). Mutant p53 Gain-of-Function in Cancer.  Cold Spring Harbor perspectives in biology. 2010, 2 (2).
  • Yosef Buganim; Hilla Solomon; Yoach Rais; Daria Kistner; Ido Nachmany; Mariana Brait; Shalom Madar; Ido Goldstein; Eyal Kalo; Nitzan Adam; Maya Gordin; Noa Rivlin; Ira Kogan; Ran Brosh; Galit Sefadia-Elad; Naomi Goldfinger; David Sidransky; Yoel Kloog; Varda Rotter (2010). p53 Regulates the Ras Circuit to Inhibit the Expression of a Cancer-Related Gene Signature by Various Molecular Pathways.  Cancer Research. 2010, 70 (6):2274-2284.
  • Xi-Song Ke; Yi Qu; Yang Cheng; Wen-Cheng Li; Varda Rotter; Anne Margrete Oyan; Karl-Henning Kalland (2010). Global profiling of histone and DNA methylation reveals epigenetic-based regulation of gene expression during epithelial to mesenchymal transition in prostate cells.  BMC Genomics. 2010, 11 .
  • Yosef Buganim; Ido Goldstein; Doron Lipson; Michael Milyavsky; Sylvie Polak-Charcon; Corine Mardoukh; Hilla Solomon; Eyal Kalo; Shalom Madar; Ran Brosh; Marina Perelman; Roy Navon; Naomi Goldfinger; Iris Barshack; Zohar Yakhini; Varda Rotter (2010). A Novel Translocation Breakpoint within the BPTF Gene Is Associated with a Pre-Malignant Phenotype.  PLoS One. 2010, 5 (3).
  • Reut Shalgi; Ran Brosh; Moshe Oren; Yitzhak Pilpel; Varda Rotter (2009). Coupling transcriptional and post-transcriptional miRNA regulation in the control of cell fate.  AGING-US. 2009, 1 (9):762-770.
  • Varda Rotter (2009). Identification and characterization of p53-associated 'gene signatures' involved in cellular transformation.  FEBS Journal. 2009, 276 :61-61.
  • Jair Bar; Rotem Feniger-Barish; Neta Moskovits; Natalia Lukashchuk; Naomi Goldfinger; Varda Rotter; Glenwood Goss; Moshe Oren (2009). Cancer cells suppress p53 in adjacent fibroblasts.  Journal of Thoracic Oncology. 2009, 4 (9):S605-S605.
  • Vered Daniel-Carmi; Efrat Makovitzki-Avraham; Eliran-Moshe Reuven; Ido Goldstein; Noga Zilkha; Varda Rotter; Esther Tzehoval; Lea Eisenbach (2009). The human 1-8D gene (IFITM2) is a novel p53 independent pro-apoptotic gene.  International Journal of Cancer. 2009, 125 (12):2810-2819.
  • Shoshana Peller; Yuval Tabach; Miri Rotschild; Osnat Garach-Joshua; Yosef Cohen; Naomi Goldfinger; Varda Rotter (2009). Identification of gene networks associated with erythroid differentiation.  Blood Cells Molecules And Diseases. 2009, 43 (1):74-80.
  • E. Marrazzo; S. Marchini; M. Tavecchio; T. Alberio; S. Previdi; E. Erba; Varda Rotter; M. Broggini (2009). The expression of the Delta Np73 beta isoform of p73 leads to tetraploidy.  European Journal of Cancer. 2009, 45 (3):443-453.
  • Oded Suad; Haim Rozenberg; Ran Brosh; Posner, Yael Diskin Posner; Naama Kessler; Linda J. W. Shimon; Felix Frolow; Atar Liran; Varda Rotter; Zippora Shakked (2009). Structural Basis of Restoring Sequence-Specific DNA Binding and Transactivation to Mutant p53 by Suppressor Mutations.  Journal of Molecular Biology. 2009, 385 (1):249-265.
  • Assaf Zemach; Laju K. Paul; Perry Stambolsky; Idan Efroni; Varda Rotter; Gideon Grafi (2009). The C-terminal domain of the Arabidopsis AtMBD7 protein confers strong chromatin binding activity.  Experimental Cell Research. 2009, 315 (20):3554-3562.
  • Ran Brosh; Varda Rotter (2009). When mutants gain new powers: news from the mutant p53 field.  Nature Reviews Cancer. 2009, 9 (10):701-713.
  • J. Bar; R. Feniger-Barish; N. Lukashchuk; H. Shaham; Neta Moskovits; Naomi Goldfinger; D. Simansky; M. Perlman; M. Papa; A. Yosepovich; G. Rechavi; Varda Rotter; Moshe Oren (2009). Cancer cells suppress p53 in adjacent fibroblasts.  Oncogene. 2009, 28 (6):933-936.
  • J. Yuan; B. M-P Yang; Z-H Zhong; I. Shats; M. Milyavsky; Varda Rotter; R. B. Lock; R. R. Reddel; K. L. MacKenzie (2009). Upregulation of survivin during immortalization of nontransformed human fibroblasts transduced with telomerase reverse transcriptase.  Oncogene. 2009, 28 (29):2678-2689.
  • Yael Aylon; N. Yabuta; H. Besserglick; Y. Buganim; Varda Rotter; H. Nojima; Moshe Oren (2009). Silencing of the Lats2 tumor suppressor overrides a p53-dependent oncogenic stress checkpoint and enables mutant H-Ras-driven cell transformation.  Oncogene. 2009, 28 (50):4469-4479.
  • Shalom Madar; Ran Brosh; Yosef Buganim; Osnat Ezra; Ido Goldstein; Hilla Solomon; Ira Kogan; Naomi Goldfinger; Helmut Klocker; Varda Rotter (2009). Modulated expression of WFDC1 during carcinogenesis and cellular senescence.  Carcinogenesis. 2009, 30 (1):20-27.
  • Ira Kogan-Sakin; Merav Cohen; Nicole Paland; Shalom Madar; Hilla Solomon; Alina Molchadsky; Ran Brosh; Yosef Buganim; Naomi Goldfinger; Helmut Klocker; Jack A. Schalken; Varda Rotter (2009). Prostate stromal cells produce CXCL-1, CXCL-2, CXCL-3 and IL-8 in response to epithelia-secreted IL-1.  Carcinogenesis. 2009, 30 (4):698-705.
  • Shalom Madar; Ido Goldstein; Varda Rotter (2009). Did Experimental Biology Die? Lessons from 30 Years of p53 Research.  Cancer Research. 2009, 69 (16):6378-6380.
  • Nicole Paland; Iris Kamer; Ira Kogan-Sakin; Shalom Madar; Naomi Goldfinger; Varda Rotter (2009). Differential Influence of Normal and Cancer-Associated Fibroblasts on the Growth of Human Epithelial Cells in an In vitro Cocultivation Model of Prostate Cancer.  Molecular Cancer Research. 2009, 7 (8):1212-1223.
  • Xi-Song Ke; Yi Qu; Kari Rostad; Wen-Cheng Li; Biaoyang Lin; Ole Johan Halvorsen; Svein A. Haukaas; Inge Jonassen; Kjell Petersen; Naomi Goldfinger; Varda Rotter; Lars A. Akslen; Anne M. Oyan; Karl-Henning Kalland (2009). Genome-Wide Profiling of Histone H3 Lysine 4 and Lysine 27 Trimethylation Reveals an Epigenetic Signature in Prostate Carcinogenesis.  PLoS One. 2009, 4 (3).
  • Yosef Buganim; Varda Rotter (2008). RHAMM in the complex p53 cell cycle network.  Cell Cycle. 2008, 7 (21):3291-3291.
  • Ran Brosh; Reut Shalgi; Atar Liran; Gilad Landan; Katya Korotayev; Giang Huong Nguyen; Espen Enerly; Hilde Johnsen; Yosef Buganim; Hilla Solomon; Ido Goldstein; Shalom Madar; Naomi Goldfinger; Anne-Lise Brresen-Dale; Doron Ginsberg; Curtis C. Harris; Yitzhak Pilpel; Moshe Oren; Varda Rotter (2008). p53-repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation.  Molecular Systems Biology. 2008, 4 .
  • Z. Salah; S. Haupt; Michael Maoz; L. Baraz; Varda Rotter; T. Peretz; Y. Haupt; R. Bar-Shavit (2008). p53 controls hPar1 function and expression.  Oncogene. 2008, 27 (54):6866-6874.
  • Xi-Song Ke; Yi Qu; Naomi Goldfinger; Kari Rostad; Randi Hovland; Lars A. Akslen; Varda Rotter; Anne Margrete Oyan; Karl-Henning Kalland (2008). Epithelial to Mesenchymal Transition of a Primary Prostate Cell Line with Switches of Cell Adhesion Modules but without Malignant Transformation.  PLoS One. 2008, 3 (10).
  • Alina Molchadsky; Igor Shats; Naomi Goldfinger; Meirav Pevsner-Fischer; Melissa Olson; Ariel Rinon; Eldad Tzahor; Guillermina Lozano; Dov Zipori; Rachel Sarig; Varda Rotter (2008). p53 Plays a Role in Mesenchymal Differentiation Programs, in a Cell Fate Dependent Manner.  PLoS One. 2008, 3 (11).
  • Gianluca Bossi; Francesco Marampon; Revital Maor-Aloni; Bianca Zani; Varda Rotter; Moshe Oren; Sabrina Strano; Giovanni Blandino; Ada Sacchi (2008). Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy.  Cell Cycle. 2008, 7 (12):1870-1879.
  • M. Germann; C. A. Rentsch; A. Wetterwald; R. Schwaninger; M. Voller; Varda Rotter; Moshe Oren; J. Schalken; G. N. Thalmann; M. G. Cecchini (2007). Differential expression of the TSC22 domain family of transcription factors in normal prostate and prostate cancer.  BJU International. 2007, 100 :26-26.
  • Michael Milyavsky; Igor Shats; Alina Cholostoy; Ran Brosh; Yosef Buganim; Lilach Weisz; Ira Kogan; Merav Cohen; Maria Shatz; Shalom Madar; Eyal Kalo; Naomi Goldfinger; Jun Yuan; Shulamit Ron; Karen MacKenzie; Amir Eden; Varda Rotter (2007). Inactivation of myocardin and p16 during malignant transformation contributes to a differentiation defect.  Cancer Cell. 2007, 11 (2):133-146.
  • L. Weisz; Moshe Oren; Varda Rotter (2007). Transcription regulation by mutant p53.  Oncogene. 2007, 26 (15):2202-2211.
  • X. Tang; M. Milyavsky; Naomi Goldfinger; Varda Rotter (2007). Amyloid-beta precursor-like protein APLP1 is a novel p53 transcriptional target gene that augments neuroblastoma cell death upon genotoxic stress.  Oncogene. 2007, 26 (52):7302-7312.
  • Shai Efrati; Sylvia Berman; Naomi Goldfinger; Neta Erez; Zhan Averbukh; Ahuva Golik; Varda Rotter; Joshua Weissgarten (2007). Enhanced angiotensin II production by renal mesangium is responsible for apoptosis/proliferation of endothelial and epithelial cells in a model of malignant hypertension.  Journal of Hypertension. 2007, 25 (5):1041-1052.
  • Eyal Kalo; Yosef Buganim; Keren E. Shapira; Hilla Besserglick; Naomi Goldfinger; Lilach Weisz; Perry Stambolsky; Yoav I. Henis; Varda Rotter (2007). Mutant p53 attenuates the SMAD-dependent transforming growth factor beta 1 (TGF-beta 1) signaling pathway by repressing the expression of TGF-beta receptor type II.  Molecular and Cellular Biology. 2007, 27 (23):8228-8242.
  • Lilach Weisz; Alexander Damalas; Michalis Liontos; Panagiotis Karakaidos; Giulia Fontemaggi; Revital Maor-Aloni; Marina Kalis; Massimo Levrero; Sabrina Strano; Vassilis G. Gorgoulis; Varda Rotter; Giovanni Blandino; Moshe Oren (2007). Mutant p53 enhances nuclear factor kappa B activation by tumor necrosis factor alpha in cancer cells.  Cancer Research. 2007, 67 (6):2396-2401.
  • Yuval Tabach; Ran Brosh; Yossi Buganim; Anat Reiner; Or Zuk; Assif Yitzhaky; Mark Koudritsky; Varda Rotter; Eytan Domany (2007). Wide-Scale Analysis of Human Functional Transcription Factor Binding Reveals a Strong Bias towards the Transcription Start Site.  PLoS One. 2007, 2 (8).
  • Igor Shats; Michael Milyavsky; Alina Cholostoy; Ran Brosh; Varda Rotter (2007). Myocardin in tumor suppression and myofibroblast differentiation.  Cell Cycle. 2007, 6 (10):1141-1146.
  • Tine Walma; Varda Rotter (2006). Spotlight on . . . Varda Rotter.  FEBS Letters. 2006, 580 (20):4763-4763.
  • C. A. Rentsch; M. Germann; A. Wetterwald; R. Schwaninger; M. Voller; Varda Rotter; Moshe Oren; J. A. Schalken; U. E. Studer; G. N. Thalmann; M. G. Cecchini (2006). Transforming growth factor stimulated clone 22 (TSC-22): Potential tumor suppressive role in prostate cancer and novel prostate basal cell marker.  European Urology Supplements. 2006, 5 (14):790-790.
  • G. W. Verhaegh; Ira Kogan; P. Kensch; K. Vandenoudenalder; F. Smit; M. Huynen; Varda Rotter; J. A. Schalken (2006). PCA/DD3, a protein-binding non-coding RNA with oncogenic properties.  European Urology Supplements. 2006, 5 (14):791-791.
  • P. Stambolsky; L. Weisz; I. Shats; Yasmin A. Klein; Naomi Goldfinger; Moshe Oren; Varda Rotter (2006). Regulation of AIF expression by p53.  Cell Death and Differentiation. 2006, 13 (12):2140-2149.
  • A Zalcenstein; L Weisz; P Stambolsky; J Bar; Varda Rotter; Moshe Oren (2006). Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53.  Oncogene. 2006, 25 (3):359-369.
  • Ira Kogan; Naomi Goldfinger; M Milyavsky; Merav Cohen; I Shats; G Dobler; H Klocker; B Wasylyk; M Voller; T Aalders; JA Schalken; Moshe Oren; Varda Rotter (2006). hTERT-immortalized prostate epithelial and stromal-derived cells: an authentic in vitro model for differentiation and carcinogenesis.  Cancer Research. 2006, 66 (7):3531-3540.
  • Yosef Buganim; Eyal Kalo; Ran Brosh; Hila Besserglick; Ido Nachmany; Yoach Rais; Perry Stambolsky; Xiaohu Tang; Michael Milyavsky; Igor Shats; Marina Kalis; Naomi Goldfinger; Varda Rotter (2006). Mutant p53 protects cells from 12-O-tetradecanoylphorbol-13-acetate-induced death by attenuating activating transcription factor 3 induction.  Cancer Research. 2006, 66 (22):10750-10759.
  • Shmuel Berman; S Efrati; Naomi Goldfinger; N Erez-Alon; Z Averbukh; A Golik; Varda Rotter; J Weissgarten (2005). Apoptosis and proliferation of renal mesangial cells from normal vs p53 knockout mice subjected to a short-term high hydrostatic pressure.  Nephrology Dialysis Transplantation. 2005, 20 :V204-V205.
  • S Efrati; Naomi Goldfinger; Shmuel Berman; N Erez-Alon; Z Averbukh; A Golik; J Weissgarten; Varda Rotter (2005). Expression of p53 gene, angiotensin-II and nitric oxide synthesis in renal mesangial cell in a model of malignant hypertension.  Nephrology Dialysis Transplantation. 2005, 20 :V39-V39.
  • S Orgad; Naomi Goldfinger; Gil Cohen; Varda Rotter; B Solomon (2005). Single chain antibody against the common epitope of mutant p53 restores wild-type activity to mutant p53 protein.  FEBS Letters. 2005, 579 (25):5609-5615.
  • Yuval Tabach; Michael Milyavsky; Igor Shats; Ran Brosh; Or Zuk; Assif Yitzhaky; Roberto Mantovani; Eytan Domany; Varda Rotter; Yitzhak Pilpel (2005). The promoters of human cell cycle genes integrate signals from two tumor suppressive pathways during cellular transformation.  Molecular Systems Biology. 2005, 1 .
  • M Milyavsky; Yuval Tabach; I Shats; Noam Erez; Yonatan Cohen; XH Tang; M Kalis; Ira Kogan; Y Buganim; Naomi Goldfinger; D Ginsberg; CC Harris; Eytan Domany; Varda Rotter (2005). Transcriptional programs following genetic alterations in p53, INK4A, and H-Ras genes along defined stages of malignant transformation.  Cancer Research. 2005, 65 (11):4530-4543.
  • A Damalas; L Weis; SH Nordgard; VN Kristensen; K Gardner; G Cheng; C Gelinas; M Levrero; S Strano; AL Borresen-Dale; Varda Rotter; Moshe Oren; G Blandino (2005). Mutant p53 exerts its gain of function through activation of the NF-kappa B pathway.  Breast Cancer Research. 2005, 7 :S53-S53.
  • Moshe Oren; E Lidor; N Minsky; P Stambolsky; J Taplick; XJ Wang; L Weisz; A Zalcenstein; Varda Rotter (2004). The role of P53 in DNA damage response and apoptosis.  Toxicology and Applied Pharmacology. 2004, 197 (3):166-167.
  • J Herkel; Naaman Kam; Noam Erez; Ayelet Mimran; A Heifetz; Miriam Eisenstein; Varda Rotter; LR Cohen (2004). Monoclonal antibody to a DNA-binding domain of p53 mimics charge structure of DNA: anti-idiotypes to the anti-p53 antibody are anti-DNA.  European Journal of Immunology. 2004, 34 (12):3623-3632.
  • Noam Erez; P Stambolsky; I Shats; M Milyavsky; T Kachko; Varda Rotter (2004). Hypoxia-dependent regulation of PHD1: cloning and characterization of the human PHD1/EGLN2 gene promoter.  FEBS Letters. 2004, 567 (3-Feb):311-315.
  • A Meerson; M Milyavsky; Varda Rotter (2004). p53 mediates density-dependent growth arrest.  FEBS Letters. 2004, 559 (3-Jan):152-158.
  • D Matas; M Milyavsky; I Shats; Lior Nissim; Naomi Goldfinger; Varda Rotter (2004). p53 is a regulator of macrophage differentiation.  Cell Death and Differentiation. 2004, 11 (4):458-467.
  • XH Tang; M Milyavsky; I Shats; Noam Erez; Naomi Goldfinger; Varda Rotter (2004). Activated p53 suppresses the histone methyltransferase EZH2 gene.  Oncogene. 2004, 23 (34):5759-5769.
  • I Shats; M Milyavsky; XH Tang; P Stambolsky; Noam Erez; Ran Brosh; Ira Kogan; I Braunstein; M Tzukerman; D Ginsberg; Varda Rotter (2004). p53-dependent down-regulation of telomerase is mediated by p21(waf1).  Journal of Biological Chemistry. 2004, 279 (49):50976-50985.
  • I Zurer; LJ Hofseth; Yonatan Cohen; M Xu-Welliver; SP Hussain; CC Harris; Varda Rotter (2004). The role of p53 in base excision repair following genotoxic stress.  Carcinogenesis. 2004, 25 (1):11-19.
  • L Weisz; A Zalcenstein; P Stambolsky; Yonatan Cohen; Naomi Goldfinger; Moshe Oren; Varda Rotter (2004). Transactivation of the EGR1 gene contributes to mutant p53 gain of function.  Cancer Research. 2004, 64 (22):8318-8327.
  • Ayelet Mimran; F Mor; Pnina Carmi; FJ Quintana; Varda Rotter; Irun R. Cohen (2004). DNA vaccination with CD25 protects rats from adjuvant arthritis and induces an antiergotypic response.  Journal of Clinical Investigation. 2004, 113 (6):924-932.
  • M Milyavsky; I Shats; Noam Erez; XH Tang; S Senderovich; A Meerson; Yuval Tabach; Naomi Goldfinger; D Ginsberg; CC Harris; Varda Rotter (2003). Prolonged culture of telomerase-immortalized human fibroblasts leads to a premalignant phenotype.  Cancer Research. 2003, 63 (21):7147-7157.
  • Noam Erez; M Milyavsky; R Eilam; G Shats; Naomi Goldfinger; Varda Rotter (2003). Expression of prolyl-hydroxylase-1 (PHD1/EGLN2) suppresses hypoxia inducible factor-1 alpha activation and inhibits tumor growth.  Cancer Research. 2003, 63 (24):8777-8783.
  • S Peller; Varda Rotter (2003). TP53 in hematological cancer: Low incidence of mutations with significant clinical relevance.  Human Mutation. 2003, 21 (3):277-284.
  • I Shats; M Milyavsky; Noam Erez; Varda Rotter (2003). The murine telomerase catalytic subunit shares the PAb-240 mutant specific epitope of the p53 protein.  FEBS Letters. 2003, 546 (3-Feb):321-324.
  • S Peller; J Frenkel; J Kahn; N Rahimi-Levene; R Yona; Lior Nissim; Naomi Goldfinger; DJ Sherman; Varda Rotter (2003). The onset of p53-dependent apoptosis plays a role in terminal differentiation of human normoblasts.  Oncogene. 2003, 22 (30):4648-4655.
  • A Zalcenstein; P Stambolsky; L Weisz; M Muller; David Wallach; TM Goncharov; PH Krammer; Varda Rotter; Moshe Oren (2003). Mutant p53 gain of function: repression of CD95(Fas/APO-1) gene expression by tumor-associated p53 mutants.  Oncogene. 2003, 22 (36):5667-5676.
  • LJ Hofseth; S Saito; SP Hussain; MG Espey; KM Miranda; Y Araki; C Jhappan; Y Higashimoto; PJ He; SP Linke; MM Quezado; I Zurer; Varda Rotter; DA Wink; E Appella; CC Harris (2003). Nitric oxide-induced cellular stress and p53 activation in chronic inflammation.  Proceedings of the National Academy of Sciences of the United States of America. 2003, 100 (1):143-148.
  • LJ Hofseth; MA Khan; M Ambrose; O Nikolayeva; M Xu-Welliver; M Kartalou; SP Hussain; RB Roth; XL Zhou; LE Mechanic; I Zurer; Varda Rotter; LD Samson; CC Harris (2003). The adaptive imbalance in base excision-repair enzymes generates microsatellite instability in chronic inflammation.  Journal of Clinical Investigation. 2003, 112 (12):1887-1894.
  • Zippora Shakked; M Yavnilovitch; AJ Kalb; Naama Kessler; R Wolkowicz; Varda Rotter; TE Haran (2002). DNA binding and 3 '-5 ' exonuclease activity in the murine alternatively-spliced p53 protein.  Oncogene. 2002, 21 (33):5117-5126.
  • Noam Erez; M Milyavsky; Naomi Goldfinger; Elior Peles; AV Gudkov; Varda Rotter (2002). Falkor, a novel cell growth regulator isolated by a functional genetic screen.  Oncogene. 2002, 21 (44):6713-6721.
  • J Herkel; JP Modrow; S Bamberger; S Kanzler; Varda Rotter; Irun R. Cohen; AW Lohse (2002). Prevalence of autoantibodies to the p53 protein in autoimmune hepatitis.  Autoimmunity. 2002, 35 (8):493-496.
  • G Lilling; J Nordenberg; Varda Rotter; Naomi Goldfinger; S Peller; Y Sidi (2002). Altered subcellular localization of p53 in estrogen-dependent and estrogen-independent breast cancer cells.  Cancer Investigation. 2002, 20 (4):509-517.
  • H Offer; Noam Erez; I Zurer; X Tang; M Milyavsky; Naomi Goldfinger; Varda Rotter (2002). The onset of p53-dependent DNA repair or apoptosis is determined by the level of accumulated damaged DNA.  Carcinogenesis. 2002, 23 (6):1025-1032.
  • H Offer; I Zurer; G Banfalvi; M Reha'k; A Falcovitz; M Milyavsky; Naomi Goldfinger; Varda Rotter (2001). p53 Modulates base excision repair activity in a cell cycle-specific manner after genotoxic stress.  Cancer Research. 2001, 61 (1):88-96.
  • J Herkel; Ayelet Mimran; Noam Erez; Naaman Kam; AW Lohse; E Marker-Hermann; Varda Rotter; Irun R. Cohen (2001). Autoimmunity to the p53 protein is a feature of systemic lupus erythematosus (SLE) related to anti-DNA antibodies.  Journal of Autoimmunity. 2001, 17 (1):63-69.
  • D Uberti; L Piccioni; M Cadei; P Grigolato; Varda Rotter; M Memo (2001). p53 is dispensable for apoptosis but controls neurogenesis of mouse dentate gyrus cells following gamma-irradiation.  Molecular Brain Research. 2001, 93 (1):81-89.
  • H Offer; M Milyavsky; Noam Erez; D Matas; I Zurer; CC Harris; Varda Rotter (2001). Structural and functional involvement of p53 in BER in vitro and in vivo.  Oncogene. 2001, 20 (5):581-589.
  • A Sigal; D Matas; N Almog; Naomi Goldfinger; Varda Rotter (2001). The C-terminus of mutant p53 is necessary for its ability to interfere with growth arrest or apoptosis.  Oncogene. 2001, 20 (35):4891-4898.
  • N Almog; M Milyavsky; F Stambolsky; A Falcovitz; Naomi Goldfinger; Varda Rotter (2001). The role of the C ' terminus of murine p53 in the p53/mdm-2 regulatory loop.  Carcinogenesis. 2001, 22 (5):779-785.
  • D Matas; A Sigal; P Stambolsky; M Milyavsky; L Weisz; D Schwartz; Naomi Goldfinger; Varda Rotter (2001). Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis.  EMBO Journal. 2001, 20 (15):4163-4172.
  • M Milyavsky; Ayelet Mimran; S Senderovich; I Zurer; Noam Erez; I Shats; Naomi Goldfinger; Ido Cohen; Varda Rotter (2001). Activation of p53 protein by telomeric (TTAGGG)(n) repeats.  Nucleic Acids Research. 2001, 29 (24):5207-5215.
  • A Seluanov; V Gorbunova; A Falcovitz; A Sigal; M Milyavsky; I Zurer; G Shohat; Naomi Goldfinger; Varda Rotter (2001). Change of the death pathway in senescent human fibroblasts in response to DNA damage is caused by an inability to stabilize p53.  Molecular and Cellular Biology. 2001, 21 (5):1552-1564.
  • A Sigal; Varda Rotter (2000). Oncogenic mutations of the p53 tumor suppressor: The demons of the guardian of the genome.  Cancer Research. 2000, 60 (24):6788-6793.
  • J Herkel; N Erez-Alon; Ayelet Mimran; R Wolkowicz; Alon Harmelin; P Ruiz; Varda Rotter; Irun R. Cohen (2000). Systemic lupus erythematosus in mice, spontaneous and induced, is associated with autoimmunity to the C-terminal domain of p53 that recognizes damaged DNA.  European Journal of Immunology. 2000, 30 (4):977-984.
  • G Lilling; H Hacohen; J Nordenberg; T Livnat; Varda Rotter; Y Sidi (2000). Differential sensitivity of MCF-7 and LCC2 cells, to multiple growth inhibitory agents: possible relation to high bcl-2/bax ratio?.  Cancer Letters. 2000, 161 (1):27-34.
  • N Almog; Naomi Goldfinger; Varda Rotter (2000). p53-dependent apoptosis is regulated by a C-terminally alternatively spliced form of murine p53.  Oncogene. 2000, 19 (30):3395-3403.
  • S Homburg; L Visochek; N Moran; F Dantzer; E Priel; E Asculai; D Schwartz; Varda Rotter; Nava Dekel; M Cohen-Armon (2000). A fast signal-induced activation of poly(ADP-ribose) polymerase: A novel downstream target of phospholipase C.  Journal of Cell Biology. 2000, 150 (2):293-307.
  • S Peller; R Halperin; D Schneider; Y Kopilova; Varda Rotter (1999). Polymorphisms of the p53 gene in women with ovarian or endometrial carcinoma.  Oncology Reports. 1999, 6 (1):193-197.
  • S Homburg; F Dantzer; N Moran; L Visochek; Nava Dekel; E Priel; D Schwartz; Varda Rotter; M Cohen-Armon (1999). A novel fast signal-transduction mechanism from cell membrane to nucleus in brain cortical neurons..  Neuroscience Letters. 1999, :S21-S21.
  • D Schwartz; Naomi Goldfinger; Zvi Kam; Varda Rotter (1999). P53 controls low DNA damage-dependent premeiotic checkpoint and facilitates DNA repair during spermatogenesis.  Cell Growth & Differentiation. 1999, 10 (10):665-675.
  • Y Yaron; D Schwartz; MI Evans; R Aloni; A Kapon; Varda Rotter (1999). p53 tumor suppressor gene expression in the mouse ovary during an artificially induced ovulatory cycle.  Journal Of Reproductive Medicine. 1999, 44 (2):107-114.
  • XL Zhou; XW Wang; LX Xu; K Hagiwara; M Nagashima; R Wolkowicz; I Zurer; Varda Rotter; CC Harris (1999). COOH-terminal domain of p53 modulates p53-mediated transcriptional transactivation, cell growth, and apoptosis.  Cancer Research. 1999, 59 (4):843-848.
  • A Sigal; D Matas; N Almog; R Li; PD Sutphin; Varda Rotter (1999). Interference of mutant p53 with drug induced apoptotic pathways.  2Nd International Congress On Gastroenterological Carcinogenesis. 1999, :211-222.
  • A Torchinsky; I Ivnitsky; S Savion; J Shepshelovich; M Gorivodsky; A Fein; H Carp; D Schwartz; J Frankel; Varda Rotter; V Toder (1999). Cellular events and the pattern of p53 protein expression following cyclophosphamide-initiated cell death in various organs of developing embryo.  Birth Defects Research Part B - Developmental and Reproductive Toxicology. 1999, 19 (5):353-367.
  • D Uberti; D Schwartz; N Almog; Naomi Goldfinger; Alon Harmelin; M Memo; Varda Rotter (1999). Epithelial cells of different organs exhibit distinct patterns of p53-dependent and p53-independent apoptosis following DNA insult.  Experimental Cell Research. 1999, 252 (1):123-133.
  • Moshe Oren; Varda Rotter (1999). Introduction: p53 - the first twenty years.  Cellular and Molecular Life Sciences. 1999, 55 (1):9-11.
  • H Offer; R Wolkowicz; D Matas; S Blumenstein; Zvi Livneh; Varda Rotter (1999). Direct involvement of p53 in the base excision repair pathway of the DNA repair machinery.  FEBS Letters. 1999, 450 (3):197-204.
  • D Uberti; Ephraim Yavin; Simone Gil; KR Ayasola; Naomi Goldfinger; Varda Rotter (1999). Hydrogen peroxide induces nuclear translocation of p53 and apoptosis in cells of oligodendroglia origin.  Molecular Brain Research. 1999, 65 (2):167-175.
  • Y Tendler; G Weisinger; R Coleman; E Diamond; S Lischinsky; Hilit Kerner; Varda Rotter; O Zinder (1999). Tissue-specific p53 expression in the nervous system.  Molecular Brain Research. 1999, 72 (1):40-46.
  • Wei Zhao; CY He; Varda Rotter; BA Merrick; JK Selkirk (1999). An intragenic deletion of nuclear localization signal-1 of p53 tumor suppressor gene results in loss of apoptosis in murine fibroblasts.  Cancer Letters. 1999, 147 (2-Jan):101-108.
  • J Frenkel; Dana Sherman; A Fein; D Schwartz; N Almog; A Kapon; Naomi Goldfinger; Varda Rotter (1999). Accentuated apoptosis in normally developing p53 knockout mouse embryos following genotoxic stress.  Oncogene. 1999, 18 (18):2901-2907.
  • N Erez-Alon; J Herkel; R Wolkowicz; PJ Ruiz; A Waisman; Varda Rotter; Irun R. Cohen (1998). Immunity to p53 induced by an idiotypic network of anti-p53 antibodies: Generation of sequence-specific anti-DNA antibodies and protection from tumor metastasis.  Cancer Research. 1998, 58 (23):5447-5452.
  • Y Yaron; D Schwartz; MI Evans; JB Lessing; Varda Rotter (1998). Alternatively spliced mRNA transcripts encoding the extracellular domain of the FSH receptor gene - Expression in the mouse ovary during the ovulatory cycle.  Journal Of Reproductive Medicine. 1998, 43 (5):435-438.
  • M Prokocimer; R Unger; HS Rennert; Varda Rotter; G Rennert (1998). Pooled analysis of p53 mutations in hematological malignancies.  Human Mutation. 1998, 12 (1):4-18.
  • S Peller; R Yona; Y Kopilova; M Prokocimer; Naomi Goldfinger; A Uysal; HG Karabulut; A Tukun; I Bokesoy; G Tuncman; Varda Rotter (1998). Molecular alterations in the TP53 gene of peripheral blood cells of patients with chronic myeloid leukemia.  Genes Chromosomes & Cancer. 1998, 21 (1):2-7.
  • D Schwartz; Varda Rotter (1998). p53-dependent cell cycle control: response to genotoxic stress.  Seminars in Cancer Biology. 1998, 8 (5):325-336.
  • Varda Rotter (1998). The role of wild type p53 in tumor protection and its loss in tumor development and progression - Introduction.  Seminars in Cancer Biology. 1998, 8 (5):315-316.
  • PJ Ruiz; R Wolkowicz; A Waisman; DL Hirschberg; Pnina Carmi; Noam Erez; H Garren; J Herkel; M Karpuj; L Steinman; Varda Rotter; Irun R. Cohen (1998). Idiotypic immunization induces immunity to mutated p53 and tumor rejection.  Nature Medicine. 1998, 4 (6):710-712.
  • RZ Li; PD Sutphin; D Schwartz; D Matas; N Almog; R Wolkowicz; Naomi Goldfinger; HP Pei; M Prokocimer; Varda Rotter (1998). Mutant p53 protein expression interferes with p53-independent apoptotic pathways.  Oncogene. 1998, 16 (25):3269-3277.
  • R Wolkowicz; Anat Peled; NB Elkind; Varda Rotter (1998). DNA-binding activity of wild-type p53 protein is mediated by the central part of the molecule and controlled by its C terminus.  Cancer Epidemiology. 1998, 22 (1):1-13.
  • M Prokocimer; S Peller; H Ben-Bassat; Naomi Goldfinger; Varda Rotter (1998). p53 gene mutation in a T-acute lymphoblastic leukemia cell line (Loucy) with t(16;20) and 5q- chromosomal aberrations.  Leukemia & Lymphoma. 1998, 29 (6-May):607-611.
  • N Almog; RZ Li; Anat Peled; D Schwartz; R Wolkowicz; Naomi Goldfinger; HP Pei; Varda Rotter (1997). The murine C'-terminally alternatively spliced form of p53 induces attenuated apoptosis in myeloid cells.  Molecular and Cellular Biology. 1997, 17 (2):713-722.
  • PA Rehberger; KH Richter; D Schwartz; Naomi Goldfinger; R Oskato; N Almog; F Marks; Varda Rotter (1997). Differential expression of the regularly spliced wild-type p53 and its COOH-terminal alternatively spliced form during epidermal differentiation.  Cell Growth & Differentiation. 1997, 8 (8):851-860.
  • R Wolkowicz; Varda Rotter (1997). The DNA binding regulatory domain of p53: See the C.  Pathologie Biologie. 1997, 45 (10):785-796.
  • N Almog; Varda Rotter (1997). Involvement of p53 in cell differentiation and development.  Biochimica Et Biophysica Acta-Reviews On Cancer. 1997, 1333 (1):F1-F27.
  • A Simons; C MelamedBessudo; R Wolkowicz; Joseph Sperling; R Sperling; Lea Eisenbach; Varda Rotter (1997). PACT: Cloning and characterization of a cellular p53 binding protein that interacts with Rb.  Oncogene. 1997, 14 (2):145-155.
  • D Schwartz; N Almog; Anat Peled; Naomi Goldfinger; Varda Rotter (1997). Role of wild type p53 in the G(2) phase: regulation of the gamma-irradiation-induced delay and DNA repair.  Oncogene. 1997, 15 (21):2597-2607.
  • Z Sthoeger; E Evron; S Goland; A Shani; R Wolkowicz; Naomi Goldfinger; Varda Rotter; M Fogel (1997). Anti-p53 autoantibodies in colon cancer patients.  B Lymphocytes And Autoimmunity. 1997, 815 :496-498.
  • Anat Peled; Dov Zipori; Varda Rotter (1996). Cooperation between p53-dependent and p53-independent apoptotic pathways in myeloid cells.  Cancer Research. 1996, 56 (9):2148-2156.
  • O Eizenberg; A FaberElman; E Gottlieb; Moshe Oren; Varda Rotter; Michal Schwartz (1996). p53 plays a regulatory role in differentiation and apoptosis of central nervous system-associated cells.  Molecular and Cellular Biology. 1996, 16 (9):5178-5185.
  • Anat Peled; D Schwartz; NB Elkind; R Wolkowicz; RZ Li; Varda Rotter (1996). The role of p53 in the induction of polyploidity of myelomonocytic leukemic M1/2 cells.  Oncogene. 1996, 13 (8):1677-1685.
  • D Ronen; D Schwartz; Y Teitz; Naomi Goldfinger; Varda Rotter (1996). Induction of HL-60 cells to undergo apoptosis is determined by high levels of wild-type p53 protein whereas differentiation of the cells is mediated by lower p53 levels.  Cell Growth & Differentiation. 1996, 7 (1):21-30.
  • D Reisman; E Balint; WT Loging; Varda Rotter; E Almon (1996). A novel transcript encoded within the 10-kb first intron of the human p53 tumor suppressor gene (D17S2179E) is induced during differentiation of myeloid leukemia cells.  Genomics. 1996, 38 (3):364-370.
  • L Schreiber; Y Sharabi; D Schwartz; Naomi Goldfinger; C Brodie; Varda Rotter; J Shoham (1996). Induction of apoptosis and p53 expression in immature thymocytes by direct interaction with thymic epithelial cells.  Scandinavian Journal of Immunology. 1996, 44 (4):314-322.
  • NB ELKIND; Naomi Goldfinger; Varda Rotter (1995). SPOT-1, A NOVEL NLS-BINDING PROTEIN THAT INTERACTS WITH P53 THROUGH A DOMAIN ENCODED BY P(CA)(N) REPEATS.  Oncogene. 1995, 11 (5):841-851.
  • Y TENDLER; Y SCHWARTZ; R RESHEF; SM SHASHA; Varda Rotter; T SHKOLNIK (1995). IMMUNOHISTOCHEMICAL DETECTION OF P53 PROTEIN EXPRESSION IN HPV-INDUCED CONDYLOMA ACUMINATUM.  Acta Dermato-Venereologica. 1995, 75 (3):177-179.
  • O EIZENBERG; A FABERELMAN; E GOTTLIEB; Moshe Oren; Varda Rotter; Michal Schwartz (1995). DIRECT INVOLVEMENT OF P53 IN PROGRAMMED CELL-DEATH OF OLIGODENDROCYTES.  EMBO Journal. 1995, 14 (6):1136-1144.
  • R ALONIGRINSTEIN; D SCHWARTZ; Varda Rotter (1995). ACCUMULATION OF WILD-TYPE P53 PROTEIN UPON GAMMA-IRRADIATION INDUCES A G(2) ARREST-DEPENDENT IMMUNOGLOBULIN-KAPPA LIGHT-CHAIN GENE-EXPRESSION.  EMBO Journal. 1995, 14 (7):1392-1401.
  • R WOLKOWICZ; NB ELKIND; D RONEN; Varda Rotter (1995). THE DNA-BINDING ACTIVITY OF WILD-TYPE P53 IS MODULATED BY BLOCKING ITS VARIOUS ANTIGENIC EPITOPES.  Oncogene. 1995, 10 (6):1167-1174.
  • S PELLER; Avital Halevy; S SLUTZKI; Y KOPILOVA; Varda Rotter (1995). P53 MUTATIONS IN MATCHED PRIMARY AND METASTATIC HUMAN TUMORS.  Molecular Carcinogenesis. 1995, 13 (3):166-172.
  • R WOLKOWICZ; Anat Peled; NB ELKIND; Varda Rotter (1995). AUGMENTED DNA-BINDING ACTIVITY OF P53 PROTEIN ENCODED BY A CARBOXYL-TERMINAL ALTERNATIVELY SPLICED MESSENGER-RNA IS BLOCKED BY P53 PROTEIN ENCODED BY THE REGULARLY SPLICED FORM.  Proceedings of the National Academy of Sciences of the United States of America. 1995, 92 (15):6842-6846.
  • S Peller; Y Kopilova; S Slutzki; Avital Halevy; K Kvitko; Varda Rotter (1995). A novel polymorphism in intron 6 of the human p53 gene: A possible association with cancer predisposition and susceptibility.  DNA and Cell Biology. 1995, 14 (12):983-990.
  • Varda Rotter; R ALONIGRINSTEIN; D SCHWARTZ; NB ELKIND; A SIMONS; R WOLKOWICZ; M LAVIGNE; P BESERMAN; A KAPON; Naomi Goldfinger (1994). DOES WILD-TYPE P53 PLAY A ROLE IN NORMAL-CELL DIFFERENTIATION.  Seminars in Cancer Biology. 1994, 5 (3):229-236.
  • A AVIRAM; R ALONIGRINSTEIN; A REPHAELI; Abraham Nudelman; M SHAKLAI; Varda Rotter (1994). INDUCTION OF P53 MESSENGER-RNA EXPRESSION IN 70Z/3 PRE-B CELLS UPON AN-9 TREATMENT.  Experimental Hematology. 1994, 22 (8):751-751.
  • Yoav Barak; A LUPO; Ayelet Zauberman; T JUVEN; R ALONIGRINSTEIN; E GOTTLIEB; Varda Rotter; Moshe Oren (1994). TARGETS FOR TRANSCRIPTIONAL ACTIVATION BY WILD-TYPE P53 - ENDOGENOUS RETROVIRAL LTR, IMMUNOGLOBULIN-LIKE PROMOTER, AND AN INTERNAL PROMOTER OF THE MDM2 GENE.  Cold Spring Harbor Symposia on Quantitative Biology. 1994, 59 :225-235.
  • M PROKOCIMER; Varda Rotter (1994). STRUCTURE AND FUNCTION OF P53 IN NORMAL-CELLS AND THEIR ABERRATIONS IN CANCER-CELLS - PROJECTION ON THE HEMATOLOGIC CELL LINEAGES.  Blood. 1994, 84 (8):2391-2411.
  • Varda Rotter; R GRINSTEINALONI; D SCHWARTZ; B ALKIND; A SIMONS; R WOLKOVITCH; P BESSERMAN; A KAPON; Naomi Goldfinger (1994). SEARCHING FOR THE FUNCTION(S) OF THE P53 SUPPRESSOR GENE IN NORMAL-CELLS.  Journal of Cellular Biochemistry. 1994, :180-180.
  • Y TENDLER; R RESHEF; Ido Cohen; M BARZILAI; SM SHASHA; Varda Rotter; T SHKOLNIK (1994). HISTOCHEMICAL-STUDIES OF PROGRESSIVE P53 MUTATIONS DURING COLONIC CARCINOGENESIS IN SPRAGUE-DAWLEY RATS INDUCED BY N-METHYL-N-NITRO-NITROSOGUANIDINE OR AZOXYMETHANE.  Pathobiology. 1994, 62 (6-May):232-237.
  • R ALONIGRINSTEIN; I ZANBAR; I ALBOUM; Naomi Goldfinger; Varda Rotter (1993). WILD-TYPE P53 FUNCTIONS AS A CONTROL PROTEIN IN THE DIFFERENTIATION PATHWAY OF THE B-CELL LINEAGE.  Oncogene. 1993, 8 (12):3297-3305.
  • D REISMAN; NB ELKIND; B ROY; J BEAMON; Varda Rotter (1993). C-MYC TRANS-ACTIVATES THE P53 PROMOTER THROUGH A REQUIRED DOWNSTREAM CACGTG MOTIF.  Cell Growth & Differentiation. 1993, 4 (2):57-65.
  • O FOORD; N NAVOT; Varda Rotter (1993). ISOLATION AND CHARACTERIZATION OF DNA-SEQUENCES THAT ARE SPECIFICALLY BOUND BY WILD-TYPE P53 PROTEIN.  Molecular and Cellular Biology. 1993, 13 (3):1378-1384.
  • N RAGIMOV; A KRAUSKOPF; N NAVOT; Varda Rotter; Moshe Oren; Y ALONI (1993). WILD-TYPE BUT NOT MUTANT-P53 CAN REPRESS TRANSCRIPTION INITIATION INVITRO BY INTERFERING WITH THE BINDING OF BASAL TRANSCRIPTION FACTORS TO THE TATA MOTIF.  Oncogene. 1993, 8 (5):1183-1193.
  • D SCHWARTZ; Naomi Goldfinger; Varda Rotter (1993). EXPRESSION OF P53 PROTEIN IN SPERMATOGENESIS IS CONFINED TO THE TETRAPLOID PACHYTENE PRIMARY SPERMATOCYTES.  Oncogene. 1993, 8 (6):1487-1494.
  • E ALMON; Naomi Goldfinger; A KAPON; D SCHWARTZ; AJ LEVINE; Varda Rotter (1993). TESTICULAR TISSUE-SPECIFIC EXPRESSION OF THE P53 SUPPRESSOR GENE.  Developmental Biology. 1993, 156 (1):107-116.
  • Varda Rotter; D SCHWARTZ; E ALMON; Naomi Goldfinger; A KAPON; A MESHORER; LA DONEHOWER; AJ LEVINE (1993). MICE WITH REDUCED LEVELS OF P53 PROTEIN EXHIBIT THE TESTICULAR GIANT-CELL DEGENERATIVE SYNDROME.  Proceedings of the National Academy of Sciences of the United States of America. 1993, 90 (19):9075-9079.
  • D REISMAN; Varda Rotter (1993). THE HELIX-LOOP-HELIX CONTAINING TRANSCRIPTION FACTOR USF BINDS TO AND TRANSACTIVATES THE PROMOTER OF THE P53 TUMOR SUPPRESSOR GENE.  Nucleic Acids Research. 1993, 21 (2):345-350.
  • Y LANDESMAN; M PAGANO; G DRAETTA; Varda Rotter; NE FUSENIG; Adi Kimchi (1992). MODIFICATIONS OF CELL-CYCLE CONTROLLING NUCLEAR PROTEINS BY TRANSFORMING GROWTH-FACTOR-BETA IN THE HACAT KERATINOCYTE CELL-LINE.  Oncogene. 1992, 7 (8):1661-1665.
  • D RONEN; Y TEITZ; Naomi Goldfinger; Varda Rotter (1992). EXPRESSION OF WILD-TYPE AND MUTANT P53 PROTEINS BY RECOMBINANT VACCINIA VIRUSES.  Nucleic Acids Research. 1992, 20 (13):3435-3441.
  • G SHAULSKY; Naomi Goldfinger; Anat Peled; Varda Rotter (1991). INVOLVEMENT OF WILD-TYPE P53 PROTEIN IN THE CELL-CYCLE REQUIRES NUCLEAR-LOCALIZATION.  Cell Growth & Differentiation. 1991, 2 (12):661-667.
  • G SHAULSKY; Naomi Goldfinger; MS TOSKY; AJ LEVINE; Varda Rotter (1991). NUCLEAR-LOCALIZATION IS ESSENTIAL FOR THE ACTIVITY OF P53 PROTEIN.  Oncogene. 1991, 6 (11):2055-2065.
  • G SHAULSKY; Naomi Goldfinger; Varda Rotter (1991). ALTERATIONS IN TUMOR-DEVELOPMENT INVIVO MEDIATED BY EXPRESSION OF WILD-TYPE OR MUTANT P53 PROTEINS.  Cancer Research. 1991, 51 (19):5232-5237.
  • Varda Rotter; M PROKOCIMER (1991). P53 AND HUMAN MALIGNANCIES.  Advances in Cancer Research. 1991, 57 :257-272.
  • D RONEN; Varda Rotter; D REISMAN (1991). EXPRESSION FROM THE MURINE P53 PROMOTER IS MEDIATED BY FACTOR BINDING TO A DOWNSTREAM HELIX-LOOP-HELIX RECOGNITION MOTIF.  Proceedings of the National Academy of Sciences of the United States of America. 1991, 88 (10):4128-4132.
  • G SHAULSKY; Naomi Goldfinger; Anat Peled; Varda Rotter (1991). INVOLVEMENT OF WILD-TYPE P53 IN PRE-B-CELL DIFFERENTIATION INVITRO.  Proceedings of the National Academy of Sciences of the United States of America. 1991, 88 (20):8982-8986.
  • OS FOORD; P BHATTACHARYA; Ziv Reich; Varda Rotter (1991). A DNA-BINDING DOMAIN IS CONTAINED IN THE C-TERMINUS OF WILD-TYPE P53-PROTEIN.  Nucleic Acids Research. 1991, 19 (19):5191-5198.
  • G SHAULSKY; Avri Ben-Ze'ev; Varda Rotter (1990). SUBCELLULAR-DISTRIBUTION OF THE P53 PROTEIN DURING THE CELL-CYCLE OF BALB/C 3T3 CELLS.  Oncogene. 1990, 5 (11):1707-1711.
  • L TRAKHTENBROT; Z KELMAN; Varda Rotter; N HARANGHERA (1990). CHROMOSOMAL MAPPING OF THE MURINE C-ABL PROTOONCOGENE BY INSITU HYBRIDIZATION.  Leukemia. 1990, 4 (2):136-137.
  • G SHAULSKY; Naomi Goldfinger; Avri Ben-Ze'ev; Varda Rotter (1990). NUCLEAR ACCUMULATION OF P53 PROTEIN IS MEDIATED BY SEVERAL NUCLEAR-LOCALIZATION SIGNALS AND PLAYS A ROLE IN TUMORIGENESIS.  Molecular and Cellular Biology. 1990, 10 (12):6565-6577.
  • D REISMAN; Varda Rotter (1989). INDUCED EXPRESSION FROM THE MOLONEY MURINE LEUKEMIA-VIRUS LONG TERMINAL REPEAT DURING DIFFERENTIATION OF HUMAN MYELOID CELLS IS MEDIATED THROUGH ITS TRANSCRIPTIONAL ENHANCER.  Molecular and Cellular Biology. 1989, 9 (8):3571-3575.
  • D REISMAN; Varda Rotter (1989). 2 PROMOTERS THAT MAP TO 5'-SEQUENCES OF THE HUMAN P53 GENE ARE DIFFERENTIALLY REGULATED DURING TERMINAL DIFFERENTIATION OF HUMAN MYELOID LEUKEMIC-CELLS.  Oncogene. 1989, 4 (8):945-953.
  • Z KELMAN; M PROKOCIMER; S PELLER; Y KAHN; G RECHAVI; Yair Manor; Ayala Cohen; Varda Rotter (1989). REARRANGEMENTS IN THE P53 GENE IN PHILADELPHIA-CHROMOSOME POSITIVE CHRONIC MYELOGENOUS LEUKEMIA.  Blood. 1989, 74 (7):2318-2324.
  • David Eliyahu; Naomi Goldfinger; O PINHASIKIMHI; G SHAULSKY; Y SKURNIK; N ARAI; Varda Rotter; Moshe Oren (1988). METH-A FIBRO-SARCOMA CELLS EXPRESS 2 TRANSFORMING MUTANT P53 SPECIES.  Oncogene. 1988, 3 (3):313-321.
  • J POHL; Naomi Goldfinger; A RADLERPOHL; Varda Rotter; V SCHIRRMACHER (1988). P53 INCREASES EXPERIMENTAL METASTATIC CAPACITY OF MURINE CARCINOMA-CELLS.  Molecular and Cellular Biology. 1988, 8 (5):2078-2081.
  • D REISMAN; Moshik Greenberg; Varda Rotter (1988). HUMAN P53 ONCOGENE CONTAINS ONE PROMOTER UPSTREAM OF EXON-1 AND A 2ND, STRONGER PROMOTER WITHIN INTRON-1.  Proceedings of the National Academy of Sciences of the United States of America. 1988, 85 (14):5146-5150.
  • Varda Rotter; M PROKOCIMER (1987). EXPRESSION OF P53 IN HUMAN-LEUKEMIA AND LYMPHOMA.  Journal of Cellular Biochemistry. 1987, :198-198.
  • O SHOHAT; Moshik Greenberg; D REISMAN; Moshe Oren; Varda Rotter (1987). INHIBITION OF CELL-GROWTH MEDIATED BY PLASMIDS ENCODING P53 ANTISENSE.  Oncogene. 1987, 1 (3):277-283.
  • M PROKOCIMER; G ELYASHIV; M SHAKLAI; Naomi Goldfinger; Varda Rotter (1987). P53 EXPRESSION IN HUMAN-LEUKEMIA AND LYMPHOMA.  Pediatric Blood and Cancer. 1987, 15 (6):322-322.
  • N ARAI; D NOMURA; K YOKOTA; D WOLF; E BRILL; O SHOHAT; Varda Rotter (1986). IMMUNOLOGICALLY DISTINCT P53 MOLECULES GENERATED BY ALTERNATIVE SPLICING.  Molecular and Cellular Biology. 1986, 6 (9):3232-3239.
  • N HARRIS; E BRILL; O SHOHAT; M PROKOCIMER; D WOLF; N ARAI; Varda Rotter (1986). MOLECULAR-BASIS FOR HETEROGENEITY OF THE HUMAN P53-PROTEIN.  Molecular and Cellular Biology. 1986, 6 (12):4650-4656.
  • M PROKOCIMER; M SHAKLAI; H BENBASSAT; D WOLF; Naomi Goldfinger; Varda Rotter (1986). EXPRESSION OF P53 IN HUMAN-LEUKEMIA AND LYMPHOMA.  Blood. 1986, 68 (1):113-118.
  • Varda Rotter; N HARRIS; D WOLF; M PROKOCIMER; Naomi Goldfinger; E BRILL; O SHOHAT (1986). EXPRESSION OF THE P53 ONCOGENE IN HUMAN TRANSFORMED-CELL LINES.  Journal of Cellular Biochemistry. 1986, :157-157.
  • GL NICOLSON; RA LABICHE; ML FRAZIER; M BLICK; RJ TRESSLER; CL READING; T IRIMURA; Varda Rotter (1986). DIFFERENTIAL EXPRESSION OF METASTASIS-ASSOCIATED CELL-SURFACE GLYCOPROTEINS AND MESSENGER-RNA IN A MURINE LARGE CELL LYMPHOMA.  Journal of Cellular Biochemistry. 1986, 31 (4):305-312.
  • C MILLER; T MOHANDAS; D WOLF; M PROKOCIMER; Varda Rotter; HP KOEFFLER (1986). HUMAN P53 GENE LOCALIZED TO SHORT ARM OF CHROMOSOME-17.  Nature. 1986, 319 (6056):783-784.
  • Varda Rotter; D WOLF (1985). BIOLOGICAL AND MOLECULAR ANALYSIS OF P53 CELLULAR-ENCODED TUMOR-ANTIGEN.  Advances in Cancer Research. 1985, 43 :113-141.
  • D WOLF; Z LAVERRUDICH; Varda Rotter (1985). INVITRO EXPRESSION OF HUMAN P53 CDNA CLONES AND CHARACTERIZATION OF THE CLONED HUMAN P53 GENE.  Molecular and Cellular Biology. 1985, 5 (8):1887-1893.
  • D WOLF; N HARRIS; Naomi Goldfinger; Varda Rotter (1985). ISOLATION OF A FULL-LENGTH MOUSE CDNA CLONE CODING FOR AN IMMUNOLOGICALLY DISTINCT P53 MOLECULE.  Molecular and Cellular Biology. 1985, 5 (1):127-132.
  • D WOLF; N HARRIS; M PROKOCIMER; Naomi Goldfinger; Varda Rotter (1985). EXPRESSION OF P53 ONCOGENE IN HUMAN TRANSFORMED-CELL LINES.  Experimental Hematology. 1985, 13 (5):447-447.
  • Varda Rotter; D WOLF; M BLICK; GL NICOLSON (1985). EXPRESSION OF ABL AND OTHER ONCOGENES IS INDEPENDENT OF METASTATIC POTENTIAL IN ABELSON VIRUS-TRANSFORMED MALIGNANT MURINE LARGE CELL LYMPHOMA.  Clinical & Experimental Metastasis. 1985, 3 (2):77-86.
  • D WOLF; Varda Rotter (1985). MAJOR DELETIONS IN THE GENE ENCODING THE P53 TUMOR-ANTIGEN CAUSE LACK OF P53 EXPRESSION IN HL-60 CELLS.  Proceedings of the National Academy of Sciences of the United States of America. 1985, 82 (3):790-794.
  • Varda Rotter; D WOLF; D PRAVTCHEVA; FH RUDDLE (1984). CHROMOSOMAL ASSIGNMENT OF THE MURINE GENE ENCODING THE TRANSFORMATION-RELATED PROTEIN-P53.  Molecular and Cellular Biology. 1984, 4 (2):383-385.
  • D WOLF; Varda Rotter (1984). INACTIVATION OF P53 GENE-EXPRESSION BY AN INSERTION OF MOLONEY MURINE LEUKEMIA VIRUS-LIKE DNA-SEQUENCES.  Molecular and Cellular Biology. 1984, 4 (7):1402-1410.
  • D WOLF; S ADMON; Moshe Oren; Varda Rotter (1984). ABELSON MURINE LEUKEMIA VIRUS-TRANSFORMED CELLS THAT LACK P53 PROTEIN-SYNTHESIS EXPRESS ABERRANT P53 MESSENGER-RNA SPECIES.  Molecular and Cellular Biology. 1984, 4 (3):552-558.
  • Varda Rotter; D WOLF; GL NICOLSON (1984). THE EXPRESSION OF TRANSFORMATION-RELATED PROTEIN P53 AND P53-CONTAINING MESSENGER-RNA IN MURINE RAW117 LARGE CELL LYMPHOMA-CELLS OF DIFFERING METASTATIC POTENTIAL.  Clinical & Experimental Metastasis. 1984, 2 (3):199-204.
  • D WOLF; N HARRIS; Varda Rotter (1984). RECONSTITUTION OF P53 EXPRESSION IN A NONPRODUCER AB-MULV-TRANSFORMED CELL-LINE BY TRANSFECTION OF A FUNCTIONAL P53 GENE.  Cell. 1984, 38 (1):119-126.
  • LF PARADA; H LAND; RA WEINBERG; D WOLF; Varda Rotter (1984). COOPERATION BETWEEN GENE ENCODING P53 TUMOR-ANTIGEN AND RAS IN CELLULAR-TRANSFORMATION.  Nature. 1984, 312 (5995):649-651.
  • Varda Rotter; Hila Abutbul; Avri Ben-Ze'ev (1983). P53 TRANSFORMATION-RELATED PROTEIN ACCUMULATES IN THE NUCLEUS OF TRANSFORMED FIBROBLASTS IN ASSOCIATION WITH THE CHROMATIN AND IS FOUND IN THE CYTOPLASM OF NON-TRANSFORMED FIBROBLASTS.  EMBO Journal. 1983, 2 (7):1041-1047.
  • Varda Rotter; Hilla Friedman; Adriana Katz; K ZERIVITZ; D WOLF (1983). VARIATION IN ANTIGENIC DETERMINANTS OF P53 TRANSFORMATION-RELATED PROTEIN OBTAINED FROM VARIOUS SPECIES.  Journal of Immunology. 1983, 131 (1):329-333.
  • Varda Rotter; Hila Abutbul; D WOLF (1983). THE PRESENCE OF P53 TRANSFORMATION-RELATED PROTEIN IN AB-MULV TRANSFORMED-CELLS IS REQUIRED FOR THEIR DEVELOPMENT INTO LETHAL TUMORS IN MICE.  International Journal of Cancer. 1983, 31 (3):315-320.
  • Varda Rotter (1983). P53, A TRANSFORMATION-RELATED CELLULAR-ENCODED PROTEIN, CAN BE USED AS A BIOCHEMICAL MARKER FOR THE DETECTION OF PRIMARY MOUSE-TUMOR CELLS.  Proceedings Of The National Academy Of Sciences Of The United States Of America-Biological Sciences. 1983, 80 (9):2613-2617.
  • Varda Rotter; Nathan Trainin (1979). ROLE OF THYMIC HORMONE (THF) AND OF A THYMIC PLASMA RECIRCULATING FACTOR (TPRF) IN THE MODULATION OF HUMAN LYMPHOCYTE-RESPONSE TO PHA AND CON A.  Journal of Immunology. 1979, 122 (2):414-420.
  • Varda Rotter; Nathan Trainin (1979). ACTIVITY OF THYMIC HORMONE AND ANOTHER FACTOR OF THYMIC ORIGIN ON THE RESPONSE OF UMBILICAL-CORD BLOOD-LYMPHOCYTES TO T-LECTINS.  Israel Medical Association Journal. 1979, 15 (2):189-190.
  • Varda Rotter; Y YAKIR; Nathan Trainin (1979). ROLE OF L-ALANINE IN THE RESPONSE OF HUMAN-LYMPHOCYTES TO PHA-A AND CON-A.  Journal of Immunology. 1979, 123 (4):1726-1731.
  • R ZAIZOV; R VOGEL; B WOLACH; B SHOHAT; Z HANDZEL; Y YAKIR; Varda Rotter; Nathan Trainin (1979). EFFECT OF THF IN IMMUNOSUPPRESSED CHILDREN WITH LYMPHO PROLIFERATIVE DISEASES.  Pediatric Research. 1979, 13 (8):954-954.
  • Varda Rotter; Avner Fink; Nathan Trainin (1978). INVITRO ALLOGENEIC RESPONSE OF HUMAN LYMPHOCYTES DEPENDENT UPON DIALYZABLE PLASMA COMPONENTS AND A THYMIC HORMONE, THF.  Cellular Immunology. 1978, 36 (2):242-250.
  • Varda Rotter; Nathan Trainin (1977). INDUCTION OF T-CELL COMPETENCE IN EXPERIMENTAL-MODELS.  Scandinavian Journal of Immunology. 1977, 6 (7-Jun):743-743.
  • Varda Rotter; Nathan Trainin (1977). EFFECT OF THYMIC HORMONE ON RESPONSE OF DIFFERENT LYMPHOID-CELL POPULATIONS TO T-MITOGENS.  Israel Medical Association Journal. 1977, 13 (4):363-370.
  • R ZAIZOV; R VOGEL; Ido Cohen; I VARSANO; B SHOHAT; Varda Rotter; Nathan Trainin (1977). THYMIC HORMONE (THF) THERAPY IN IMMUNOSUPPRESSED CHILDREN WITH LYMPHOPROLIFERATIVE NEOPLASIA AND GENERALIZED VARICELLA.  Biomedicine Express. 1977, 27 (3):105-108.
  • I VARSANO; TM SCHONFELD; Y MATOTH; B SHOHAT; T ENGLANDER; Varda Rotter; Nathan Trainin (1977). SEVERE DISSEMINATED ADENOVIRUS INFECTION SUCCESSFULLY TREATED WITH A THYMIC HUMORAL FACTOR, THF.  Acta Paediatrica Scandinavica. 1977, 66 (3):329-331.
  • M SCHLESINGER; Varda Rotter; Sarit Levin; Nathan Trainin (1976). MECHANISMS OF ACTIVATION OF NEWBORN HUMAN CELLS BY THYMUS HUMORAL FACTOR AND PLASMA DIALYSATES.  Israel Medical Association Journal. 1976, 12 (10):1233-1234.
  • Varda Rotter; M SCHLESINGER; R KALDERON; Nathan Trainin (1976). RESPONSE OF HUMAN LYMPHOCYTES TO PHA AND CON-A, DEPENDENT ON AND REGULATED BY THF, A THYMIC HORMONE.  Journal of Immunology. 1976, 117 (5):1927-1932.
  • Y LEVO; Varda Rotter; B RAMOT (1975). RESTORATION OF CELLULAR IMMUNE-RESPONSE BY LEVAMISOLE IN PATIENTS WITH HODGKINS-DISEASE.  Biomedicine. 1975, 23 (6):198-200.
  • Varda Rotter; Nathan Trainin (1975). INCREASED MITOGENIC REACTIVITY OF LYMPHOID-CELLS TO T LECTINS INDUCED BY THYMUS HUMORAL FACTOR.  Israel Medical Association Journal. 1975, 11 (12):1381-1382.
  • Varda Rotter; Nathan Trainin (1975). ELIMINATION OF SUPPRESSOR T-CELLS IN MICE UNDERGOING A GRAFT VERSUS HOST REACTION EXPRESSED BY INCREASED RESPONSE TO POLYVINYLPYRROLIDONE (PVP).  Cellular Immunology. 1975, 18 (1):199-209.
  • Varda Rotter; Nathan Trainin (1975). INCREASED MITOGENIC REACTIVITY OF NORMAL SPLEEN-CELLS TO T-LECTINS INDUCED BY THYMUS HUMORAL FACTOR (THF).  Cellular Immunology. 1975, 16 (2):413-421.
  • Varda Rotter; Nathan Trainin (1975). INHIBITION OF TUMOR-GROWTH IN SYNGENEIC CHIMERIC MICE MEDIATED BY A DEPLETION OF SUPPRESSOR T-CELLS.  Transplantation. 1975, 20 (1):68-74.
  • Varda Rotter; Nathan Trainin (1974). SUPPRESSOR-T CELLS REGULATE RESPONSE TO POLYVINYLPYRROLIDONE.  Israel Medical Association Journal. 1974, 10 (9):1178-1178.
  • Nathan Trainin; Y LEVO; Varda Rotter (1974). RESISTANCE TO HYDROCORTISONE CONFERRED UPON THYMOCYTES BY THYMIC HUMORAL FACTOR.  European Journal of Immunology. 1974, 4 (9):634-637.
  • Varda Rotter; Nathan Trainin (1974). THYMUS-CELL POPULATION EXERTING A REGULATORY FUNCTION IN IMMUNE-RESPONSE OF MICE TO POLYVINYL PYRROLIDONE.  Cellular Immunology. 1974, 13 (1):76-86.
  • P LONAI; B MOGILNER; Varda Rotter; Nathan Trainin (1973). STUDIES ON EFFECT OF A THYMIC HUMORAL FACTOR ON DIFFERENTIATION OF THYMUS-DERIVED LYMPHOCYTES.  European Journal of Immunology. 1973, 3 (1):21-26.
  • Varda Rotter; I NAKAMURA; Nathan Trainin (1973). STUDIES ON CHARACTERIZATION OF LYMPHOID TARGET CELL FOR ACTIVITY OF A THYMUS HUMORAL FACTOR.  Journal of Experimental Medicine. 1973, 138 (1):130-142.